Literature DB >> 32732635

Ruxolitinib Response in an Infant With Very-early-onset Inflammatory Bowel Disease and Gain-of-function STAT1 Mutation.

Karen P Acker1, Rachel Borlack2, Alina Iuga3, Helen E Remotti3, Craig R Soderquist3, Satoshi Okada4, Miyuki Tsumura4, Jean-Laurent Casanova5, Joseph Picoraro6, Anne Puel7, Sivan Kinberg6, Yesim Demirdag6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32732635     DOI： 10.1097/MPG.0000000000002854

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN： 0277-2116            Impact factor:   2.839


× No keyword cloud information.
  4 in total

1.  Three Adult Cases of STAT1 Gain-of-Function with Chronic Mucocutaneous Candidiasis Treated with JAK Inhibitors.

Authors:  Emilie W Borgström; Marie Edvinsson; Lucía P Pérez; Anna C Norlin; Sara L Enoksson; Susanne Hansen; Anders Fasth; Vanda Friman; Olle Kämpe; Robert Månsson; Hernando Y Estupiñán; Qing Wang; Tan Ziyang; Tadepally Lakshmikanth; Carl Inge E Smith; Petter Brodin; Peter Bergman
Journal:  J Clin Immunol       Date:  2022-09-02       Impact factor: 8.542

2.  Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations.

Authors:  Pilar Blanco Lobo; Paloma Guisado-Hernández; Isabel Villaoslada; Beatriz de Felipe; Carmen Carreras; Hector Rodriguez; Begoña Carazo-Gallego; Ana Méndez-Echevarria; José Manuel Lucena; Pilar Ortiz Aljaro; María José Castro; José Francisco Noguera-Uclés; Joshua D Milner; Katelyn McCann; Ofer Zimmerman; Alexandra F Freeman; Michail S Lionakis; Steven M Holland; Olaf Neth; Peter Olbrich
Journal:  J Clin Immunol       Date:  2022-05-04       Impact factor: 8.542

3.  Ruxolitinib: Targeted Approach for Treatment of Autoinflammatory Very Early Onset Inflammatory Bowel Disease.

Authors:  Sharmistha Rudra; Eliana Shaul; Maire Conrad; Trusha Patel; Astrela Moore; Noor Dawany; Megan C Canavan; Kathleen E Sullivan; Edward Behrens; Judith R Kelsen
Journal:  Clin Gastroenterol Hepatol       Date:  2021-07-27       Impact factor: 13.576

Review 4.  Impact of JAK Inhibitors in Pediatric Patients with STAT1 Gain of Function (GOF) Mutations-10 Children and Review of the Literature.

Authors:  Olaf Neth; Peter Olbrich; Angela Deyà-Martínez; Jaques G Rivière; Pérsio Roxo-Junior; Jan Ramakers; Markéta Bloomfield; Paloma Guisado Hernandez; Pilar Blanco Lobo; Soraya Regina Abu Jamra; Ana Esteve-Sole; Veronika Kanderova; Ana García-García; Mireia Lopez-Corbeto; Natalia Martinez Pomar; Andrea Martín-Nalda; Laia Alsina
Journal:  J Clin Immunol       Date:  2022-04-29       Impact factor: 8.542
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.